Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Jakob Obermüller"'
Autor:
Enrique M. Ocio, Yvonne A. Efebera, Roman Hájek, Jan Straub, Vladimir Maisnar, Jean-Richard Eveillard, Lionel Karlin, María-Victoria Mateos, Albert Oriol, Vincent Ribrag, Paul G. Richardson, Stefan Norin, Jakob Obermüller, Nicolaas A. Bakker, Luděk Pour
Publikováno v:
Haematologica, Vol 109, Iss 3 (2023)
Melphalan flufenamide (melflufen), a first-in-class, alkylating peptide-drug conjugate, demonstrated clinical benefit in combination with dexamethasone in triple-class refractory multiple myeloma (MM). The phase I/IIa ANCHOR study evaluated melflufen
Externí odkaz:
https://doaj.org/article/2fc23bce08c444d98389254c7b7873ab
Autor:
Enrique Maria Ocio San Miguel, Yvonne A. Efebera, Roman Hájek, Jan Straub, Vladimir Maisnar, Jean-Richard Eveillard, Lionel Karlin, Maria-Victoria Mateos, Albert Oriol, Vincent Ribrag, Paul Richardson, Stefan Norin, Jakob Obermüller, Nicolaas A. Bakker, Ludek Pour
Publikováno v:
HemaSphere, Vol 7, p e2842627 (2023)
Externí odkaz:
https://doaj.org/article/e8b2fb37406c41c09b0b8b4194d694ec
Autor:
Pieter Sonneveld, Johan Harmenberg, Sara Bringhen, Paul G. Richardson, Peter M. Voorhees, Catriona Byrne, Brandi Reeves, Ulf-Henrik Mellqvist, Torben Plesner, Eva Nordström, Jakob Obermüller
Publikováno v:
Bringhen, S, Voorhees, P M, Plesner, T, Mellqvist, U-H, Reeves, B, Sonneveld, P, Byrne, C, Nordström, E, Harmenberg, J, Obermüller, J & Richardson, P G 2021, ' Melflufen plus dexamethasone in relapsed/refractory multiple myeloma : long-term survival follow-up from the Phase II study O-12-M1 ', British Journal of Haematology, vol. 193, no. 6, pp. 1105-1109 . https://doi.org/10.1111/bjh.17302
British Journal of Haematology
British Journal of Haematology
Summary An updated survival analysis was conducted for the Phase II study O‐12‐M1 of melphalan flufenamide (melflufen) plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) with two or more prior lines of therapy (includ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70e85b5ff4c125b9690f74ca7c52f85d
https://findresearcher.sdu.dk:8443/ws/files/190556676/Open_Access_Version.pdf
https://findresearcher.sdu.dk:8443/ws/files/190556676/Open_Access_Version.pdf
Autor:
Miquel Granell, Luděk Pour, Malin Sydvander, Vladimir Maisnar, Jakob Obermüller, Enrique M. Ocio, Stefan Norin, Roman Hájek, Paul G. Richardson
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S425-S426
Context Development of resistance to standard treatments for RRMM highlights the need for novel therapies. Melphalan flufenamide (melflufen) is a first-in-class peptide–drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb7d6a87097c71f3eecaa4b0f1e495a4
https://doi.org/10.1016/s2152-2650(21)01951-0
https://doi.org/10.1016/s2152-2650(21)01951-0
Autor:
Roman Hájek, Luděk Pour, Miquel Granell, Vladimir Maisnar, Paul G Richardson, Stefan Norin, Malin Sydvander, Jakob Obermüller, Enrique M Ocio
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S251
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a697acdcc626a49a4ef8fe8e6e207c69
https://doi.org/10.1016/s2152-2650(21)01574-3
https://doi.org/10.1016/s2152-2650(21)01574-3
Autor:
Xavier Leleu, Adrian Alegre, Paul G. Richardson, Albert Oriol, Agne Paner, John W. Hiemenz, Christopher Maisel, Amitabha Mazumder, Hani Hassoun, Sara Thuresson, Jakob Obermüller, Maria-Victoria Mateos, Maxim Norkin, Catriona Byrne, Paula Rodriguez-Otero, Joan Biade, Michele Cavo, Johan Harmenberg, Omar Nadeem, Anastasios Raptis, Cyrille Touzeau, Alessandra Larocca, Noemi Puig
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S295-S296
Context: Outcomes in RRMM remain poor (Kumar et al. Leukemia. 2017; 31:2443), and treatment options are limited for RRMM refractory to multiple drug classes (Gandhi et al. Leukemia. 2019; 33:2266). Melphalan flufenamide (melflufen) is a first-in-clas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5dbcf3887e63028795ebbce48800aaec
https://doi.org/10.1016/s2152-2650(20)30932-0
https://doi.org/10.1016/s2152-2650(20)30932-0
Autor:
Paul G. Richardson, Jakob Obermüller, Stefan Norin, Miquel Granell, Enrique M. Ocio, Vladimir Maisnar, Roman Hájek, Luděk Pour, Malin Sydvander
Publikováno v:
Journal of Clinical Oncology. 39:8037-8037
8037 Background: Development of resistance to standard treatments for RRMM highlights the need for novel therapies. Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate (PDC) that leverages aminopeptidases and rapidly releases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ccbdb091fcc3f3f1fedc128bd957b76
https://doi.org/10.1200/jco.2021.39.15_suppl.8037
https://doi.org/10.1200/jco.2021.39.15_suppl.8037
Autor:
Johan Harmenberg, Sara Bringhen, Torben Plesner, Peter M. Voorhees, Catriona Byrne, Paul G. Richardson, Eva Nordström, Pieter Sonneveld, Ulf-Henrik Mellqvist, Brandi Reeves, Jakob Obermüller
Publikováno v:
Bringhen, S, Voorhees, P M, Plesner, T, Mellqvist, U-H, Reeves, B, Sonneveld, P, Byrne, C, Nordström, E, Harmenberg, J, Obermüller, J & Richardson, P G 2019, ' Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) : Results from the Phase 2 Study O-12-M1 ', Blood, vol. 134, no. Suppl. 1, 1839 . https://doi.org/10.1182/blood-2019-124828
Background: Patients with multiple myeloma (MM) who have relapsed after conventional treatment have limited therapeutic options for long-term disease control. Melflufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly cytot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e318ad3ca6aa5fcfbaaf5bff69681a4
https://doi.org/10.1182/blood-2019-124828
https://doi.org/10.1182/blood-2019-124828
Autor:
Jakob Obermüller, Paul G. Richardson, Yvonne A. Efebera, Miquel Granell, Maria-Victoria Mateos, Malin Sydvander, Stefan Norin, Enrique M. Ocio, Vladimir Maisnar, Lionel Karlin, Luděk Pour, Albert Oriol, Roman Hájek
Publikováno v:
Blood
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Background: MM remains an incurable disease with current therapeutic options, demonstrating the need for novel therapies. Melflufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly cytotoxic payload into myeloma cells throu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cb0c5c3b5e5de85b5a78691af0817e9
https://doi.org/10.1182/blood-2019-124815
https://doi.org/10.1182/blood-2019-124815
Autor:
Torben Plesner, Paul G. Richardson, Johan Harmenberg, Sara Bringhen, Jeffrey A. Zonder, Brandi Reeves, Jakob Obermüller, Pieter Sonneveld, Ulf-Henrik Mellqvist, Stojan Zavisic, Peter M. Voorhees
Publikováno v:
Journal of Clinical Oncology. 37:8043-8043
8043 Background: Melflufen is a novel peptide-conjugated alkylator potentiated by intracellular aminopeptidases, which are markedly overexpressed in MM. Melflufen + dex had encouraging activity in pts with RRMM and ≥2 prior lines of therapy in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f07e877b9597bd4f9db908c2b34b0d01
https://doi.org/10.1200/jco.2019.37.15_suppl.8043
https://doi.org/10.1200/jco.2019.37.15_suppl.8043